Table 3.

Comparison of the efficacy of pharmacological interventions for controlling myopia progression

Medicine	Type	Effect (slowing down the progression of myopia)	Side effect	Others
Atropine	Non-selective M receptor antagonist	56-96%	Photophobia, blurred vision, and decreased accommodative amplitude (with high concentration)	Concentration-dependent, 0.05% shows significant efficacy with minimal side effects
Pirenzepine	Selective M receptor antagonist	Effectively reduces refractive power but does not reduce axial eye growth	No significant side effects	Low corneal permeability, not suitable for clinical treatment
Apomorphine	Non-selective dopamine receptor agonist	Inhibits the development of form-deprivation myopia	Safety requires further verification	Limited research, primarily used in animal studies
7-MX	Non-selective antagonist of adenosine receptors	50%	No significant side effects	Dose-dependent, studies conducted only in Denmark

7-MX: 7-Methylxanthine.